Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells

被引:34
作者
Gonzalez, R
Vereecque, R
Wickham, TJ
Facon, T
Hetuin, D
Kovesdi, I
Bauters, F
Fenaux, P
Quesnel, B
机构
[1] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[2] IRCL, INSERM U124, F-59045 Lille, France
[3] Genvex Inc, Rockville, MD 20852 USA
关键词
D O I
10.1089/10430349950016753
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Adenoviral vectors can efficiently infect myeloma cell lines, but transduction of fresh myeloma cells performed at low multiplicity of infections (MOIs) showed only partial efficacy. The modified adenoviral vector AdZ.F(pK7), through binding of polylysines to heparan sulfate-containing receptors, could increase virus adsorption and gene transfer efficiency in myeloma cells, which express heparan sulfate-containing receptors, Thus, we investigated the ability of AdZ.F(pK7) vector to achieve efficient gene transfer in primary cultured fresh myeloma cells, Transduction of 16 primary cultured myeloma samples showed that gene transfer was much more efficient with AdZ.F(pK7) than with control AdZ.F. Both addition of soluble heparin and cell treatment,vith heparinase I dramatically inhibited gene transfer in myeloma cells by AdZ.F(pK7) but had no effect with AdZ.F, while addition of recombinant fiber protein inhibited AdZ.F but not AdZ.F(pK7), confirming that AdZ.F(pK7) gene transfer in myeloma cells is mediated by the targeting of heparan sulfates, AdZ.F(pK7) transduction of bone marrow cells showed that myeloma cells and hematopoietic progenitor AC133-, CD34-, and CD33-positive cells were efficiently transduced at an MOI of 100, but that only myeloma cells were significantly transduced at an MOI of 12. Thus, AdZ.F(pK7) vector seems to be well suited for immunological approaches of gene therapy or bone marrow-purging applications in multiple myeloma.
引用
收藏
页码:2709 / 2717
页数:9
相关论文
共 20 条
[1]   The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses [J].
Bergelson, JM ;
Krithivas, A ;
Celi, L ;
Droguett, G ;
Horwitz, MS ;
Wickham, T ;
Crowell, RL ;
Finberg, RW .
JOURNAL OF VIROLOGY, 1998, 72 (01) :415-419
[2]   Adenovirus vectors for gene transduction into mobilized blood CD34+ cells [J].
Bregni, M ;
Shammah, S ;
Malaffo, F ;
Di Nicola, M ;
Milanesi, M ;
Magni, M ;
Matteucci, P ;
Ravagnani, F ;
Jordan, CT ;
Siena, S ;
Gianni, AM .
GENE THERAPY, 1998, 5 (04) :465-472
[3]   CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors [J].
de Wynter, EA ;
Buck, D ;
Hart, C ;
Heywood, R ;
Coutinho, LH ;
Clayton, A ;
Rafferty, JA ;
Burt, D ;
Guenechea, G ;
Bueren, JA ;
Gagen, D ;
Fairbairn, LJ ;
Lord, BI ;
Testa, NG .
STEM CELLS, 1998, 16 (06) :387-396
[4]   Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation [J].
Dhodapkar, MV ;
Abe, E ;
Theus, A ;
Lacy, M ;
Langford, JK ;
Barlogie, B ;
Sanderson, RD .
BLOOD, 1998, 91 (08) :2679-2688
[5]   Cancer gene therapy: Connecting basic research with clinical inquiry [J].
Dranoff, G .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2548-2556
[6]   Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein [J].
Gonzalez, R ;
Vereecque, R ;
Wickham, TJ ;
Vanrumbeke, M ;
Kovesdi, I ;
Bauters, F ;
Fenaux, P ;
Quesnel, B .
GENE THERAPY, 1999, 6 (03) :314-320
[7]   Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma [J].
Kopantzev, E ;
Roschke, V ;
Rudikoff, S .
HUMAN GENE THERAPY, 1998, 9 (01) :13-19
[8]  
MARAGLIA S, 1997, BLOOD, V90, P5013
[9]  
MARINI F, 1998, AM SOC HEMATOLOGY, P92
[10]   Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy [J].
Mittereder, N ;
March, KL ;
Trapnell, BC .
JOURNAL OF VIROLOGY, 1996, 70 (11) :7498-7509